Alembic Pharma gets USFDA nod for generic high blood pressure treatment drug
on Friday said it has received final approval from the US health regulator for its generic version of
amlodipine and atorvastatin
tablets, used to treat high blood pressure. The final approval by the US Food & Drug Administration (USFDA) is for the
abbreviated new drug application
(ANDA) of Amlodipine and Atorvastatin tablets of strengths 2.5 mg/10 mg, 2.5 mg/20 mg, 2.5 mg/40 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 5 mg/80 mg, 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg, and 10 mg/80 mg, the company said in a statement.
These are therapeutically equivalent to the reference-listed drug product,
Caduet tablets
of corresponding strengths of Pharmacia and Upjohn Co LLC, it added.
Alembic said it has a cumulative total of 223
ANDA approvals
(199 final approvals and 24 tentative approvals) from the USFDA.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
7 hours ago
- Business Standard
Natco Pharma receives USFDA EIR for Hyderabad API facility
Natco Pharma informed that the U.S. Food and Drug Administration (US FDA) has issued an EIR for its active pharmaceutical ingredient (API) division located in Mekaguda, Hyderabad, Telangana. The US FDA had conducted an inspection at the companys aforementioned unit from 9 June to 13 June 2025. Post the inspection, the company received one observation in Form-483, which was classified as voluntary action indicated (VAI). In a regulatory filing made during market hours today, Natco Pharma announced that it has received an establishment inspection report (EIR) for its API facility located in Mekaguda. NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The companys consolidated net profit increased 5.3% to Rs 406.60 crore on a 14.3% jump in revenue from operations to Rs 1,221 crore in Q4 FY25 over Q4 FY24. Shares of Natco Pharma slipped 3% to Rs 1,003.75 on the BSE.
Business Standard
7 hours ago
- Business Standard
Zydus receives USFDA tentative approval for Ibrutinib tablets
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Ibrutinib tablets 140 mg, 280 mg, and 420 mg (USRLD: Imbruvica tablets, 140 mg, 280 mg and 420 mg). Ibrutinib is a kinase inhibitor indicated for the treatment of adult patients with Chronic lymphocytic leukaemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion, and Waldenstrom's macroglobulinemia (WM). Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad. Ibrutinib tablets had annual sales of USD 2148.9 mn in the United States (IQVIA MAT May 2025). The group now has 420 approvals and has so far filed 484 ANDAs since the commencement of the filing process in FY 2003-04.
Business Standard
9 hours ago
- Business Standard
Zydus Lifesciences gets USFDA Nod for Ibrutinib tablets
Zydus Lifesciences informed that it has received tentative approval from the United States Food and Drug Administration (USFDA) for Ibrutinib tablets 140 mg, 280 mg, and 420 mg. Ibrutinib is a kinase inhibitor indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) with a 17p deletion, and Waldenstr's macroglobulinemia (WM). Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad. The tablets had annual sales of $2,148.9 million in the United States (IQVIA MAT May 2025). The group now holds 420 approvals and has filed a total of 484 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. Shares of Zydus Lifesciences rose 0.78% to currently trade at Rs 969.15 on the BSE.
